Effects of the FABP2 A54T mutation on triglyceride metabolism of viscerally obese men.
OBJECTIVE
Viscerally obese individuals are frequently characterized by a proatherogenic condition. A missense mutation (A54T) in the fatty acid binding protein type 2 (FABP2) gene has been associated with insulin resistance and obesity. This study examined the effect of this mutation on lipoprotein levels in viscerally obese hyperinsulinemic condition.


METHODS
A total of 217 men were assigned to one of two groups based on their FABP2 A54T polymorphism.


RESULTS
The two genotypic groups showed no difference in either physiological characteristics or lipoprotein/lipid profile, before or after statistical adjustment for age. From this initial sample, 50 men accepted to have their postprandial lipid response assessed and 10 T54/A54 heterozygotes were then individually matched for visceral adipose tissue accumulation and fasting plasma triglyceride (TG) levels with 10 A54/A54 homozygotes. High-density lipoprotein (HDL)-TG levels were significantly increased in the fasting state as well as 4 hours after the test meal (p = 0.04 and p = 0.0008, respectively) in men bearing the A54T mutation. In addition, the area under the curve of postprandial HDL-TG levels was also significantly higher among T54/A54 heterozygotes than among A54/A54 homozygotes (p = 0.04). Interestingly, fasting TG concentrations in large TG-rich lipoproteins (large-TRL; S(f) > 400) were correlated with HDL-TG levels at 4 (r = 0.74, p = 0.01) and 8 hours (r = 0.73, p = 0.01) after the test meal in T54/A54 heterozygotes only.


CONCLUSIONS
The FABP2 A54T missense mutation may contribute to the TG enrichment of HDL in the postprandial state that, in turn, may alter the risk of atherosclerotic vascular disease.
Berthier
M T
MT
Lipid Research Center, Laval University Medical Research Center, Sainte-Foy, Québec, Canada.
Couillard
C
C
Prud'homme
D
D
Nadeau
A
A
Bergeron
J
J
Tremblay
A
A
Després
J P
JP
Vohl
M C
MC
D000273:Adipose Tissue; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D001823:Body Composition; D002352:Carrier Proteins / Q000235:genetics*; D015331:Cohort Studies; D004041:Dietary Fats; D005215:Fasting; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D005502:Food; D006579:Heterozygote; D006801:Humans; D007328:Insulin / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D009363:Neoplasm Proteins; D009765:Obesity / Q000097:blood / Q000235:genetics*; D014280:Triglycerides / Q000097:blood*; D025521:Tumor Suppressor Proteins; D014781:Viscera
D001786:Blood Glucose; D002352:Carrier Proteins; D004041:Dietary Fats; C493404:FABP2 protein, human; C107608:FABP7 protein, human; C493405:Fabp2 protein, mouse; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D007328:Insulin; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D009363:Neoplasm Proteins; D014280:Triglycerides; D025521:Tumor Suppressor Proteins